Background: Serum total bilirubin (TB) is a potent antioxidant and may be a negative risk factor of cardiovascular disease. In non-diabetic adults, hemoglobin A1c (HbA1c), but not fasting plasma glucose, is an independent risk factor of cardiovascular disease.
Methods and Results:Linear regression using TB as a dependent variable and cardiovascular risk factors, including HbA1c, as independent variables, linear regression using HbA1c as a dependent variable and other cardiovascular risk factors, including TB, as independent variables, and logistic regression using the highest decile (≥5.4%) of HbA1c as a dependent variable and TB and other cardiovascular risk factors as independent variables were performed for 893 apparently healthy male smokers, 1,607 male nonsmokers, and 1,680 women. The standardized regression coefficient of HbA1c for TB and that of TB for HbA1c was -0.12 (P=0.007) and -0.06 (P=0.02), respectively, in the smokers, -0.20 (P<0.0001) and -0.07 (P<0.0001), respectively, in the nonsmokers, and -0.21 (P< 0.0001) and -0.14 (P<0.0001), respectively, in the women. The odds ratio of 1 SD increment in TB for HbA1c ≥5.4% was not significant in the smokers, 0.67 (P=0.002) in the nonsmokers, and 0.55 (P<0.0001) in the women.
Conclusions:Bilirubin was negatively associated with HbA1c independently of other cardiovascular risk factors in apparently healthy Japanese men and women. The association was weak in male smokers. (Circ J 2011; 75: 190 - 195 Bilirubin, A1c, and CVD
Methods
SubjectsBetween April 2008 and March 2010, 3,401 men and 2,095 women visited Medical Check-up Center, Tachikawa Medical Center, for general health screening. Among them 3,375 men and 2,069 women signed informed consent. Excluding subjects with a history of CVD or who were taking antidiabetic, antihypertensive, or antihyperlipidemic medication from those who gave consent, the resulting 2,500 men and 1,680 women comprised the subjects in the present study, which is part of the study on obesity-related cardiovascular risk factors at Tachikawa Medical Center. Data collected at the first visit were used for subjects who visited 2 or more times. The protocol for the study was approved by the ethics committee at Tachikawa Medical Center and written informed consent was given by each subject.